Egetis Therapeutics Logo

Egetis Therapeutics

ISIN: SE0003815604 | Ticker: EGTX | LEI: 549300RZCKGWRUBPMY22

About Egetis Therapeutics

Company Description

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Companyโ€™s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum T3 levels and secondary clinical endpoints. As a result of fruitful regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in the first half of 2023 based on existing clinical data.

Year founded



Klara Norra Kyrkogata 26, 11122 Stockholm โ€“ Sweden

Filings & Publications

Shareholder information

Shares outstanding



Oct. 31, 2019

Stock exchange(s)

Nasdaq Stockholm



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.